Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Date:12/11/2012

redict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Note: Data in this release correspond to ASH Abstract 904.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
9. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
10. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader in ... immunotherapy to treat a variety of cancers, today announced ... BVCF, a China -based healthcare private ... company focused on the development of new therapeutics for ... Shanghai Cancer Institute and Shanghai Renji Hospital, the company ...
(Date:11/26/2014)... -- At the American Dental Association,s Annual Meeting in ... Group was honored to be part of the 2014 ... see and test the Best of Class winners and ... the latest developments in dental technology. This year, featured ... Caries Detection Device and Kerr Demi ™  Ultra ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... Aug. 4 Tolerx, Inc. , a ... and cancer by modulating T cell activity, today announced ... Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment ... research and early-stage product development programs involving novel therapies ...
... Healthcare, Inc. (Nasdaq: GRMH ) will host a conference ... , to discuss the company,s financial results for Q2, 2010. Management will review ... , , , ... be webcast on the investor relations section of Graymark,s website at http://www.graymarkhealthcare.com ...
Cached Medicine Technology:Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 2Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 3Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 4Graymark Healthcare, Inc. to Host Conference Call to Discuss Q2 Financial Results 2
(Date:11/26/2014)... 26, 2014 With a redesign of ... Steven Meier has enhanced the user experience and ... prospective patients an online destination for orthopedic and sports ... present the new and improved version of the website. ... easier than ever for current and prospective patients to ...
(Date:11/26/2014)... ISI Telemanagement Solutions, Inc., a leading ... the 2014 Lync Pioneer Award by ... a great honor to ISI, who continues to ... ISI offers an integrated collaboration reporting and recording ... voice, video, Lync IM, and conferencing. , ...
(Date:11/26/2014)... For those with a New Year’s resolution to get in ... at the University of Colorado Anschutz Health and Wellness Center ... 45- 60 minute classes have just started and are included ... memberships. , LES MILLS BODYPUMP™ exercise classes strengthen, condition and ... fast results , By focusing on low weight loads ...
(Date:11/26/2014)... Youngsters who enter puberty early are at increased risk ... was linked with a number of factors associated with ... according to the researchers. Early puberty was also linked ... peers, and having friends who were prone to getting ... found an association between early puberty and these factors, ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... and Drug Administration will have many restaurant chains posting calorie ... movie theater popcorn and ice cream parlor fare. "Americans ... often consuming less nutritious food and underestimating the calories they ... afternoon news conference. Although listing calorie counts on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 2Health News:Calorie Counts Mandated at Chain Restaurants, FDA Says 3
... , MONDAY, March 28 (HealthDay News) -- Teenagers ... likely to start using marijuana by the time they,re 17, ... birth cohort study that began in 1994 found that by ... and 12 percent of boys had used marijuana or other ...
... San Diego School of Medicine claim that the availability of ... that surgery should become an important part of the primary ... C. Chang, PhD, MPH, MBA, director of Outcomes Research in ... out that surgery in the United States continues to be ...
... ANN ARBOR, Mich. Most women face only a small ... treatment. Yet a new study from the University of Michigan ... speak little English expressed a great deal of worry about ... for some women, these worries can be so strong that ...
... recognizes and neutralizes or destroys toxins and foreign pathogens ... result when the system attacks the body,s own tissues ... sclerosis (MS). MS is a serious condition in which ... spinal cord are destroyed as a result of misdirected ...
... , SUNDAY, March 27 (HealthDay News) -- Baseball ... finds a new study. Researchers analyzed data from more ... and found that pitchers whose teammates were hit by a ... the temperature reached 90 degrees F than on cooler days. ...
... study published today provides a new perspective on the Great ... there were remarkable improvements in life expectancy of over five ... was actually associated with an increase in suicides but reduction ... the current recession in Europe and the U.S. The study, ...
Cached Medicine News:Health News:Surgeon availability tied to survival rate in vehicle crashes 2Health News:Some women worry too much about breast cancer returning, U-M study finds 2Health News:A possible new target for treatment of multiple sclerosis 2Health News:A possible new target for treatment of multiple sclerosis 3Health News:Great Depression did not significantly improve life expectancy in the US 2
... Single Use reloadable linear stapler with ... PI™ disposable stapler is designed for use ... healthy internal tissues. The instrument places a ... when using the 30 VASCULAR cartridges) of ...
... Single Use Loading Units With ... ILA™ 75 (Single Use Reloadable ... ,INDICATIONS The ILA™ 75 single-use ... for use in the resection, ...
... 75 single-use stapler, anastomotic type, is ... transection, and/or the anastomosis of normal, ... ILA™ 75 single-use stapler, anastomotic type, ... resection, transection, and/or the anastomosis of ...
... The PROXIMATE HCS Procedure for Prolapse and ... of titanium staples in 33mm diameter size. ... canal for transection and resection of internal ... surgical treatment of hemorrhoidal disease. The PPH01 ...
Medicine Products: